Viking Therapeutics, Inc. (NASDAQ:) director J. Matthew Singleton conducted a sale of company stock worth more than $715,000, according to a recent SEC filing. In the transactions, which occurred on September 20, 2024, Singleton sold 10,300 shares of Viking Therapeutics common stock at a price of $69.50 per share.
The sale came after Singleton acquired the same number of shares through an option exercise at a price of $1.19 per share, for a total investment of $12,257. After the sale, Singleton’s direct ownership in the company decreased to 9,500 shares of common stock.
The filing noted that these trades were executed under a prearranged Rule 10b5-1 trading plan, which allows company insiders to establish predetermined trading plans to buy or sell certain amounts of stock at a predetermined time.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Investors often monitor insider transactions because they provide insight into executives’ confidence in the company’s prospects and can sometimes indicate the future direction of the stock price.
In other recent news, Viking Therapeutics has made notable progress with its drug candidate VK2735. The oral medication, developed as a weight loss treatment, has shown favorable results in early tolerance, according to Morgan Stanley. The company’s positive outlook is supported by initial Phase 1 data showing weight loss of up to 5.3% at the highest dose of 40 mg over four weeks, with a remarkably clean safety profile. These data contrast favorably with the findings of Roche’s CT-996, which reported increased gastrointestinal side effects at higher doses.
The safety profile of VK2735 has been highlighted, especially as higher doses have recently been administered without safety concerns. The upcoming Obesity Week conference will provide updated Phase 1 data for VK2735 at increased doses of 60 mg, 80 mg and 100 mg. The updated data is expected to demonstrate even greater weight loss while maintaining tolerability, which could lead to Viking Therapeutics initiating a Phase 2 study in the fourth quarter of 2024.
Additionally, JPMorgan initiated coverage on Viking Therapeutics shares with an Overweight rating. The company’s analysis shows that oral-2735 could capture approximately 10% of the large US oral obesity market. This projection is supported by the drug’s promising profile, which the company says has not yet been fully taken into account in Viking Therapeutics’ current stock valuation. Additionally, Truist Securities maintained a Buy rating on Viking Therapeutics, with a consistent price target of $120.00, suggesting that Viking’s commercial prospects for its GLP1 product, VK2735, could be incrementally positive following Eli Lilly’s (NYSE: ).
InvestingPro Insights
As Viking Therapeutics (NASDAQ:VKTX) continues to navigate the biopharmaceutical landscape, recent insider activity has caught investors’ attention. Director J. Matthew Singleton’s share sale coincides with notable financial figures and analyst sentiment that can provide broader context for potential investors.
Data from InvestingPro shows that Viking Therapeutics has a market capitalization of approximately $7.76 billion, underscoring its significant presence in the sector despite its clinical-stage status. The company’s price-to-book ratio for the trailing twelve months from Q2 2024 is 8.48, indicating a premium valuation compared to the book value of its assets. Furthermore, Viking Therapeutics has demonstrated a strong one-year total price return of 429.45%, reflecting robust investor confidence and market performance over the past year.
Two InvestingPro Tips that are particularly relevant to the article are:
- Viking Therapeutics was trading at a high Price to Book multiple, which corresponds to the premium price at which the director sold his shares.
- The company has delivered strong returns over the past year, which may have been a good time for Singleton to take advantage of the stock’s appreciation.
These insights, in addition to the 12 additional InvestingPro Tips available at https://www.investing.com/pro/VKTX, can serve as valuable tools for investors exploring the dynamics behind Viking Therapeutics’ stock movements and the potential implications of trades with want to understand prior knowledge. .
It’s worth noting that while analysts have upgraded their earnings for the coming period, they don’t expect the company to be profitable this year. This combination of investor optimism and the reality of financial performance is a crucial factor to consider when assessing Viking Therapeutics’ future prospects.
The company’s next earnings date is set for October 30, 2024, which will likely provide further insight into its operational success and strategic direction, potentially impacting investor sentiment and stock valuation.
This article was produced with the support of AI and reviewed by an editor. For more information see our General Terms and Conditions.
